Rhythm Pharmaceuticals

OverviewSuggest Edit

Rhythm Pharmaceuticals is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders.
TypePublic
Founded2008
HQBoston, MA, US
Websiterhythmtx.com

Latest Updates

Employees (est.) (Nov 2017)22(+23%)
Share Price (May 2021)$22.1
Cybersecurity ratingBMore

Key People/Management at Rhythm Pharmaceuticals

Nithya Desikan

Nithya Desikan

Chief Commercial Officer
Hunter Smith

Hunter Smith

Chief Financial Officer
Simon Kelner

Simon Kelner

Chief Human Resources Officer
Murray Stewart

Murray Stewart

Chief Medical Officer
David Meeker

David Meeker

Chairman, President and Chief Executive Officer
Show more

Rhythm Pharmaceuticals Office Locations

Rhythm Pharmaceuticals has an office in Boston
Boston, MA, US (HQ)
222 Berkeley St # 12
Show all (1)

Rhythm Pharmaceuticals Financials and Metrics

Rhythm Pharmaceuticals Revenue

USD

Net income (Q3, 2017)

(10.0m)

EBIT (Q3, 2017)

(8.3m)

Market capitalization (7-May-2021)

1.1b

Closing stock price (7-May-2021)

22.1

Cash (30-Sept-2017)

27.9m
Rhythm Pharmaceuticals's current market capitalization is $1.1 b.
Annual
USDFY, 2015FY, 2016

General and administrative expense

3.4m6.3m

R&D expense

7.1m19.6m

Operating expense total

10.6m25.9m

EBIT

(10.6m)(25.9m)
Quarterly
USDQ3, 2016Q3, 2017

General and administrative expense

982.0k2.3m

R&D expense

5.4m6.0m

Operating expense total

6.4m8.3m

EBIT

(6.4m)(8.3m)
Annual
USDFY, 2015FY, 2016

Cash

34.9m6.5m

Prepaid Expenses

623.0k638.0k

Current Assets

35.5m11.2m

PP&E

17.0k930.0k
Quarterly
USDQ2, 2017Q3, 2017

Cash

8.7m27.9m

Prepaid Expenses

722.0k1.6m

Current Assets

18.5m32.0m

PP&E

822.0k845.0k
Annual
USDFY, 2015FY, 2016

Net Income

(11.1m)(25.9m)

Depreciation and Amortization

144.0k

Accounts Payable

893.0k467.0k

Cash From Operating Activities

(7.0m)(23.2m)
Quarterly
USDQ2, 2016Q3, 2016Q2, 2017Q3, 2017

Net Income

(11.1m)(17.5m)(13.2m)(23.2m)

Depreciation and Amortization

33.0k89.0k108.0k163.0k

Accounts Payable

882.0k(335.0k)(602.0k)830.0k

Cash From Operating Activities

(12.6m)(17.0m)(13.2m)(21.6m)
USDFY, 2015

Financial Leverage

-4.7 x
Show all financial metrics

Rhythm Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

Rhythm Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Rhythm Pharmaceuticals Online and Social Media Presence

Embed Graph

Rhythm Pharmaceuticals News and Updates

Rhythm Pharmaceuticals to Present at BofA Securities 2021 Virtual Health Care Conference

BOSTON, May 05, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the treatment paradigm for people living with rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and…

Rhythm Pharmaceuticals Reports First Quarter 2021 Financial Results

-- First U.S. commercial sales of IMCIVREE™ (setmelanotide) completed late in first quarter –

Rhythm Pharmaceuticals to Present at 20th Annual Needham Virtual Healthcare Conference

BOSTON, April 07, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., Chair, President and Chief Executive…

Rhythm Pharmaceuticals Announces Late-Breaking Data Presentations at ENDO 2021

BOSTON, March 09, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that three late-breaking abstracts have been accepted for pre…

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results

-- Received FDA approval of IMCIVREE™ (setmelanotide), the first-ever therapy for chronic weight management in patients with obesity due to POMC, PCSK1 or LEPR deficiency -- -- Announced positive topline data from Phase 3 pivotal trial evaluating setmelanotide in Bardet-Biedl and Alström syndromes; …

Rhythm Pharmaceuticals to Present at Cowen & Co. 41st Annual Health Care Conference

BOSTON, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that David Meeker, M.D., President and Chief Executive Officer…
Show more

Rhythm Pharmaceuticals Blogs

Rhythm Pharmaceuticals Presents New Data from Phase 2 Basket Study Showing Continued Weight Loss at Up to Nine Months in Patients with HET Obesity on Setmelanotide at ENDO 2021

-- Responders with HET obesity achieved mean weight loss of greater than 12 percent at nine months on setmelanotide therapy -- -- Additional poster presentations include Phase 3 data in Bardet-Biedl and Alström syndromes and analyses of adverse events   in Phase 2 and Phase 3 studies in POMC,

Rhythm Pharmaceuticals Announces Sale of Priority Review Voucher for $100M

BOSTON , Jan. 05, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that it has entered into a definitive agreement to sell its

Rhythm Pharmaceuticals Announces New Clinical Data on Setmelanotide at ObesityWeek® 2020

Rhythm Pharmaceuticals Announces New Clinical Data on Setmelanotide at ObesityWeek® 2020 Content Import Wed, 11/04/2020 - 16:31 Rhythm Pharmaceuticals Announces New Clinical Data on Setmelanotide at ObesityWeek® 2020 November 4, 2020 at 4:30 PM EST This releas…

Rhythm Pharmaceuticals Reports Third Quarter 2020 Financial Results

Rhythm Pharmaceuticals Reports Third Quarter 2020 Financial Results Content Import Mon, 11/02/2020 - 08:02 Rhythm Pharmaceuticals Reports Third Quarter 2020 Financial Results November 2, 2020 at 8:00 AM EST This release is a backfill from a News Wire …

Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trials of Setmelanotide in The Lancet Diabetes & Endocrinology

Largest studies in POMC and LEPR deficiency obesities demonstrate that treatment with setmelanotide reduced body weight and hunger BOSTON , Oct. 30, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing

Rhythm Pharmaceuticals Appoints Yann Mazabraud as Executive Vice President, Head of International

– Company announces organizational changes designed to accelerate global strategy – Yann Mazabraud , Executive Vice President, Head of International BOSTON , Sept. 14, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a late-stage biopharmaceutical company aimed at developing and
Show more

Rhythm Pharmaceuticals Frequently Asked Questions

  • When was Rhythm Pharmaceuticals founded?

    Rhythm Pharmaceuticals was founded in 2008.

  • Who are Rhythm Pharmaceuticals key executives?

    Rhythm Pharmaceuticals's key executives are Nithya Desikan, Hunter Smith and Simon Kelner.

  • How many employees does Rhythm Pharmaceuticals have?

    Rhythm Pharmaceuticals has 22 employees.

  • Who are Rhythm Pharmaceuticals competitors?

    Competitors of Rhythm Pharmaceuticals include Alembic Pharmaceuticals, EMS Pharma and Biocon.

  • Where is Rhythm Pharmaceuticals headquarters?

    Rhythm Pharmaceuticals headquarters is located at 222 Berkeley St # 12, Boston.

  • Where are Rhythm Pharmaceuticals offices?

    Rhythm Pharmaceuticals has an office in Boston.

  • How many offices does Rhythm Pharmaceuticals have?

    Rhythm Pharmaceuticals has 1 office.